Breaking News Instant updates and real-time market news.

KITE

Kite Pharma

$56.41

1.57 (2.86%)

, RHHBY

Roche

$30.83

0.13 (0.42%)

08:33
10/06/16
10/06
08:33
10/06/16
08:33

Kite Pharma initiates phase 1b/2 combination study for KTE-C19, atezolizumab

Kite Pharma (KITE) announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentech's anti-PD-L1 cancer immunotherapy. The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma. PD-L1 expression in DLBCL is associated with high-risk disease and poor outcomes. The interaction of PD-L1 and PD-1, which is expressed on KTE-C19, may dampen T-cell activity in some patients. As a result, use of the two compounds in combination could provide a synergistic effect since inhibiting PD-L1 with atezolizumab may enhance and prolong the activity and proliferation of KTE-C19. Kite entered a clinical collaboration in March 2016 with Genentech, a member of the Roche Group (RHHBY), to evaluate the safety and efficacy of KTE-C19 in combination with atezolizumab. The first ZUMA-6 patient was enrolled at the end of September 2016.

KITE

Kite Pharma

$56.41

1.57 (2.86%)

RHHBY

Roche

$30.83

0.13 (0.42%)

  • 07

    Oct

  • 18

    Oct

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

KITE Kite Pharma
$56.41

1.57 (2.86%)

09/27/16
RBCM
09/27/16
NO CHANGE
RBCM
Kite Pharma data positive, says RBC Capital
RBC Capital analyst Michael Yee says that Kite reported positive Phase II data for its KTE-C19 drug in DLBCL with a 47% complete response rate which beat expectations. The analyst says that the complete response rate "is very supportive of FDA approval." He keeps an Outperform rating on the shares.
09/27/16
COWN
09/27/16
NO CHANGE
COWN
Outperform
Efficacy of Kite's KTE-C19 'impressive,' safety 'acceptable,' says Cowen
Cowen analyst Eric Schmidt thinks the 33% complete remissions rate at three months in chemorefractory aggressive NHL patients in Kite Pharma's ZUMA-1 trial is "impressive" and that the safety experience in the trial is "acceptable." The two deaths reported in the trial need to be considered not only in the context of the treatment's efficacy but also in the context of the disease, said Schmidt, who continues to model KTE-C19 as a greater than $1B product and keeps an Outperform rating on Kite Pharma shares.
09/27/16
STFL
09/27/16
NO CHANGE
STFL
Kite Pharma data much better than standard of care, says Stifel
Stifel analyst Thomas Shrader says that Kite reported a complete response rate of 52% for its KTE-C19 drug in DLBCL, versus the standard of care's complete response rate of about 8%. The analyst says that the results exceed the level needed for FDA approval. He keeps a $74 price target and Buy rating on the shares.
09/27/16
LEER
09/27/16
NO CHANGE
LEER
Outperform
Kite's ZUMA-1 interim data incrementally positive for Juno, says Leerink
Leerink analyst Michael Schmidt says Kite Pharma's (KITE) top-line interim results from its pivotal ZUMA-1 trial of anti-CD19 CAR-T product KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma, or DLBCL, are incrementally positive for Juno Therapeutics (JUNO). While Juno is roughly one year behind Kite in DLBCL, the analyst believes its JCAR017 holds the promise to have a compelling safety/efficacy profile in lymphoma and Acute Lymphoblastic Leukemia. He reiterates an Outperform rating on Juno's shares.
RHHBY Roche
$30.83

0.13 (0.42%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

NRZ

New Residential

$16.85

0.31 (1.87%)

13:46
04/26/17
04/26
13:46
04/26/17
13:46
Options
New Residential call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

PGH

Pengrowth Energy

$1.01

-0.0065 (-0.64%)

13:45
04/26/17
04/26
13:45
04/26/17
13:45
Upgrade
Pengrowth Energy rating change  »

Pengrowth Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXL

Sunoco Logistics

$24.29

-0.065 (-0.27%)

, ETP

Energy Transfer Partners

$36.37

-0.05 (-0.14%)

13:43
04/26/17
04/26
13:43
04/26/17
13:43
Hot Stocks
Energy Transfer Partners holders approve Sunoco Logistics merger »

Sunoco Logistics Partners…

SXL

Sunoco Logistics

$24.29

-0.065 (-0.27%)

ETP

Energy Transfer Partners

$36.37

-0.05 (-0.14%)

ETE

Energy Transfer Equity

$19.33

0.78 (4.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 23

    May

XOM

Exxon Mobil

$81.98

0.25 (0.31%)

13:43
04/26/17
04/26
13:43
04/26/17
13:43
Hot Stocks
Exxon Mobil raises dividend to 77c from 75c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

ATVI

Activision Blizzard

$51.36

0.48 (0.94%)

13:39
04/26/17
04/26
13:39
04/26/17
13:39
Hot Stocks
Activision Blizzard unveils next 'Call of Duty,' says launching November 3 »

Activision Blizzard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

NTRA

Natera

$8.62

0.26 (3.11%)

13:33
04/26/17
04/26
13:33
04/26/17
13:33
Hot Stocks
Natera, Cancer Research UK publish results from 100 patients in TRACERx study »

Natera and Cancer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

HCLP

Hi-Crush Partners

$15.05

-0.05 (-0.33%)

13:33
04/26/17
04/26
13:33
04/26/17
13:33
Options
Hi Crush Partners calls are active ahead of earnings »

Hi Crush Partners calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

NFLX

Netflix

$152.16

8.33 (5.79%)

, FB

Facebook

$146.49

1.02 (0.70%)

13:32
04/26/17
04/26
13:32
04/26/17
13:32
Hot Stocks
FCC chairman Pai proposes to roll back net neutrality rules »

As previewed in recent…

NFLX

Netflix

$152.16

8.33 (5.79%)

FB

Facebook

$146.49

1.02 (0.70%)

AMZN

Amazon.com

$907.62

0.21 (0.02%)

GOOG

Alphabet

$872.30

9.54 (1.11%)

GOOGL

Alphabet Class A

$888.84

9.91 (1.13%)

CMCSA

Comcast

$38.49

0.48 (1.26%)

CMCSK

Comcast

T

AT&T

$40.11

0.17 (0.43%)

VZ

Verizon

$47.29

0.5937 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 08

    May

  • 09

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 17

    May

  • 22

    May

  • 23

    May

  • 05

    Jun

MPLX

MPLX

$36.39

-0.26 (-0.71%)

13:31
04/26/17
04/26
13:31
04/26/17
13:31
Hot Stocks
MPLX raises quarterly distribution 4% to 54c per unit »

MPLX LP announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

CREE

Cree

$24.82

0.07 (0.28%)

, IFNNY

Infineon

$20.70

0.12 (0.58%)

13:29
04/26/17
04/26
13:29
04/26/17
13:29
Recommendations
Cree, Infineon analyst commentary  »

Roth Capital says Cree…

CREE

Cree

$24.82

0.07 (0.28%)

IFNNY

Infineon

$20.70

0.12 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 09

    May

IART

Integra LifeSciences

$43.74

0.86 (2.01%)

13:27
04/26/17
04/26
13:27
04/26/17
13:27
Recommendations
Integra LifeSciences analyst commentary  »

Integra LifeSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    Jun

AA

Alcoa

$36.37

-0.12 (-0.33%)

, KALU

Kaiser Aluminum

$83.84

-0.05 (-0.06%)

13:26
04/26/17
04/26
13:26
04/26/17
13:26
Periodicals
Commerce Secretary to announce plan to investigate aluminum imports, CNBC says »

Commerce Secretary Wilbur…

AA

Alcoa

$36.37

-0.12 (-0.33%)

KALU

Kaiser Aluminum

$83.84

-0.05 (-0.06%)

CENX

Century Aluminum

$13.62

0.99 (7.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZIOP

ZIOPHARM

$7.09

0.25 (3.66%)

13:26
04/26/17
04/26
13:26
04/26/17
13:26
Options
Ziopharm call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 02

    Jun

  • 06

    Jun

13:20
04/26/17
04/26
13:20
04/26/17
13:20
General news
Treasury Action: yields jerked higher »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

13:17
04/26/17
04/26
13:17
04/26/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
04/26/17
04/26
13:16
04/26/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
04/26/17
04/26
13:15
04/26/17
13:15
General news
5-Yr Note Auction Coupon Rate data reported »

5-Yr Note Auction Coupon…

13:15
04/26/17
04/26
13:15
04/26/17
13:15
General news
Treasury's $34 B 5-year sale was poor, as feared »

Treasury's $34 B…

13:14
04/26/17
04/26
13:14
04/26/17
13:14
General news
5-Yr Note Auction Total Amount data reported »

5-Yr Note Auction Total…

13:14
04/26/17
04/26
13:14
04/26/17
13:14
General news
Export Prices data reported. »

April Export Prices at % …

13:14
04/26/17
04/26
13:14
04/26/17
13:14
General news
Import Prices data reported. »

April Import Prices at % …

EEM

MSCI Emerging Markets Index

$40.04

-0.16 (-0.40%)

13:11
04/26/17
04/26
13:11
04/26/17
13:11
Options
Notable put spreads in the iShares Emerging Markets ETF »

Notable put spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$227.78

1.15 (0.51%)

, BAC

Bank of America

$24.08

0.095 (0.40%)

13:08
04/26/17
04/26
13:08
04/26/17
13:08
Periodicals
Fed looks to restructure big bank supervision panel, WSJ says »

The Fed is restructuring…

GS

Goldman Sachs

$227.78

1.15 (0.51%)

BAC

Bank of America

$24.08

0.095 (0.40%)

C

Citi

$60.43

0.2199 (0.37%)

WFC

Wells Fargo

$54.90

0.335 (0.61%)

JPM

JPMorgan

$88.61

0.345 (0.39%)

MS

Morgan Stanley

$44.65

0.38 (0.86%)

USB

U.S. Bancorp

$52.36

0.225 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 09

    May

  • 11

    May

  • 19

    May

  • 22

    May

  • 31

    May

  • 06

    Jun

  • 13

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

X

U.S. Steel

$23.27

-7.84 (-25.20%)

13:06
04/26/17
04/26
13:06
04/26/17
13:06
Downgrade
U.S. Steel rating change  »

U.S. Steel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CCCR

China Commercial Credit

$1.82

0.4101 (29.09%)

13:06
04/26/17
04/26
13:06
04/26/17
13:06
Syndicate
Breaking Syndicate news story on China Commercial Credit »

China Commercial Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.